C12N 2730/10133
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2730/10133 (Use of viral protein as therapeutic agent other than vaccine) appears on 19 US grants and 35 published applications in this corpus.
Search patents in C12N- Granted patents
- 19
- Published applications
- 35
- Assignees
- 19
- Inventors
- 43
- Latest grant
- 16 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 5 |
| 2017 | 1 | 1 |
| 2018 | 1 | 4 |
| 2019 | 3 | 3 |
| 2020 | 1 | 3 |
| 2021 | 1 | 5 |
| 2022 | 2 | 2 |
| 2023 | 3 | 2 |
| 2024 | 3 | 2 |
| 2025 | 3 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Therapeutic vaccine for hepatitis b virus (HBV) using the HBV core antigen16 Dec 2025US 12,496,339 B2Abacus Bioscience, Inc.
- Compositions and methods for treating viral infections3 Jun 2025US 12,319,714 B2G Tech Bio LLC
- Hepatitis B virus replication inhibitor and pharmaceutical composition for treating hepatitis B comprising the same15 Apr 2025US 12,275,759 B2Riken
- Modified antimicrobial peptide derived from an arginine-rich domain10 Sep 2024US 12,084,479 B2Academia Sinica
- T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof11 Jun 2024US 12,006,348 B2Cue Biopharma, Inc.
- Compositions and methods for treating viral infections23 Jul 2026US 2026/0209279 A1G Tech Bio LLC
- Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereof6 Mar 2025US 2025/0074950 A1Board of Regents, The University of Texas System
- T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use Thereof12 Dec 2024US 2024/0409606 A1Cue Biopharma, Inc.
- Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core Antigen18 Apr 2024US 2024/0123061 A1Abacus Bioscience, Inc.
- Compositions and methods for treating metabolic diseases28 Dec 2023US 2023/0414706 A1Shanghai Hep Pharmaceutical Co., Ltd.
Most cited
By later US patents
- Hepatitis B virus pre-S1 derived synthetic polypeptides and uses thereof6US 7,892,754 B2Institut National De La Sante Et De La Recherche Medicale (Inserm) · 2011
- Antimicrobial peptides derived from hepatitis B virus core protein arginine-rich domain1US 10,214,564 B2Academia Sinica · 2019
- Hepatitis B virus pre-S1 derived synthetic polypeptides and uses thereof1US 10,323,068 B2Institut National De La Sante Et De La Recherche Medicale (Inserm) · 2019
- Therapy of atherosclerosis, primary biliary cirrhosis and NRLP3 inflammasome-associated disease by HTCP inhibitors1US 10,925,925 B2Myr GmbH · 2021
- Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen1US 11,324,819 B2Abacus Bioscience, Inc. · 2022